-
Mashup Score: 3Aditya Bardia, MD, on Destiny-Breast06: An Additional Analysis - 9 hour(s) ago
Aditya Bardia, MD, of UCLA David Geffen School of Medicine, Los Angeles, presents the additional analysis of the efficacy and safety of trastuzumab deruxtecan vs physician’s choice of chemotherapy by pace of disease progression on prior endocrine-based therapy from DESTINY-Breast06 (Abstract LB1-04). Disclaimer: This video transcript has not been proofread or edited and may contain errors. DESTINY-Breast06 was a pivotal phase III trial that looked at T-DXd or trastuzumab deruxtecan, a HER2-directed ADC
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 2Matthew S. Davids, MD, MMSc, on Triplet Therapy of Acalabrutinib, Venetoclax, and Obinutuzumab: Focus on TP53-Aberrant CLL - 6 day(s) ago
Matthew S. Davids, MD, MMSc, of Dana-Farber Cancer Institute, Boston, discusses the primary endpoint evaluation of a phase II trial of the triplet regimen of acalabrutinib, venetoclax, and obinutuzumab in a population of patients with TP53 -aberrrant chronic lymphocytic leukemia (CLL). The triplet was active and well tolerated as a front-line therapy, Dr. Davids noted, and these findings support its use for such patients with high-risk CLL (Abstract 1865). Disclaimer: This video transcript has not been
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet-
Learn about the results of a phase II trial of triplet therapy for CLL using acalabrutinib, venetoclax, and obinutuzumab in this video from @ASH_hematology 2024 with Matthew S. Davids, MD, MMSc of @DanaFarber. https://t.co/CEufC1uzrd #CLL #ASH2024 #leusm https://t.co/wOQ4YsMBIN
-
-
Mashup Score: 3
The American Society of Clinical Oncology elected Elizabeth A. Mittendorf, MD, PhD, MHCM, FASCO, to lead as its President beginning in June 2026. Dr. Mittendorf, a long-time ASCO member and
Source: society.asco.orgCategories: General Medicine News, Oncologists1Tweet-
Elizabeth A. Mittendorf, MD, PhD, MHCM, FASCO was elected to serve as @ASCO president for the 2026-27 term. 6 other members were also elected to the ASCO Board of Directors and Nominating Committee. Find more details here: https://t.co/LdWzSqUKaJ #oncology
-
-
Mashup Score: 3
Nikolaos Katsivelos, MD, and John Levine, MD, MS, of Icahn School of Medicine at Mount Sinai report on an investigation into the potential for serial monitoring of graft-versus-host disease (GVHD) symptom severity and MAGIC algorithm probabilities in patients with clinical and biomarker-defined low-risk GVHD to further risk-stratify patients into clinically meaningful groups (Abstract 380). Disclaimer: This video transcript has not been proofread or edited and may contain errors. Dr. Levine: Acute
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet-
Learn all about the potential for serial monitoring of graft-versus-host disease symptom severity in this video from @ASH_hematology 2024 featuring Nikolaos Katsivelos, MD, and John Levine, MD, MS. https://t.co/N5jRBeekV1 #ASH2024 #GVHD https://t.co/tGuMeXNYiD
-
-
Mashup Score: 4Kathryn Newlin, RN, MSN, ANP-BC, on Updates in HR-Positive, HER2-Negative Metastatic Breast Cancer - 9 day(s) ago
Kathryn Newlin, RN, MSN, ANP-BC, of Washington University in St. Louis, discusses her presentation on HR+ HER2- metastatic breast cancer from the JADPRO Live conference recently held in Grapevine, Texas. Kathryn covers factors involved in treatment selection for this patient population, including key agents in the armamentarium, relevant biomarkers and the emergence of HER2 low as a factor in added treatment options, and the management of adverse effects. Disclaimer: This video transcript has not been
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet-
Check out this video from the 2024 @JADPRO Live conference featuring Kathryn Newlin, RN, MSN, ANP-BC, of Washington University discussing HR+ HER2- metastatic breast cancer. https://t.co/Pko2kirwrR #bcsm #breastcancer https://t.co/u7QvZeKaQV
-
-
Mashup Score: 5Danielle Wolfe Cohen, MD, on Mechanisms of Relapse in B-Cell Acute Lymphoblastic Leukemia - 10 day(s) ago
Danielle Wolfe Cohen, MD, of the William L. Carroll Laboratory at New York University Grossman School of Medicine, describes data illuminating the role of an inflammatory phenotype in driving clonal evolution in B-cell acute lymphoblastic leukemia. The new findings may indicate promising avenues for further research on treatment resistance and disease relapse (Abstract 633). Disclaimer: This video transcript has not been proofread or edited and may contain errors. I am here today at the American Society
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet-
In this video from @ASH_hematology 2024, Danielle Wolfe Cohen, MD, discusses research into an inflammatory phenotype in driving clonal evolution in B-cell acute lymphoblastic leukemia. https://t.co/kTrdAmriEk #ash2024 #leusm #leukemia https://t.co/1YIu6jbAwT
-
-
Mashup Score: 2Cara Norelli, MS, AGNP-C, on Managing Dermatologic Side Effects in Patients With Cancer - 10 day(s) ago
Cara Norelli, MS, AGNP-C, of Memorial Sloan Kettering Cancer Center, discusses her presentation on dermatologic toxicities seen in patients with cancer from the JADPRO Live conference recently held in Grapevine, Texas. Ms. Norelli covers the importance of knowing the distinguishing characteristics among the different types of rashes or lesions often seen in patients receiving cancer treatment, identifying dermatologic emergencies, and maintaining communication with patients to properly manage dermatologic
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet-
Patients with #cancer need a range of care. In this video from @JADPRO Live 2024 Cara Norelli, MS, AGNP-C discusses dermatologic side effects of treatment. https://t.co/mQD5WFrIR5 #jadprolive24 https://t.co/3jHdoGdHLQ
-
-
Mashup Score: 3Sibylle Loibl, MD, PhD, on Primary Results of the Randomized, Phase III PADMA Study in HER2-Negative/HR-Positive Metastatic Breast Cancer - 13 day(s) ago
Sibylle Loibl, MD, PhD, of the German Breast Group, Neu-Isenburg, Germany, presented primary results of the randomized phase III PADMA trial comparing first-line endocrine therapy plus palbociclib vs standard mono-chemotherapy in women with high-risk HER2-negative/HR-positive metastatic breast cancer and indication for chemotherapy (Abstract LB1-03). Disclaimer: This video transcript has not been proofread or edited and may contain errors. The PADMA study investigated whether an endocrine-based treatment
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet-
Hear about the primary results of the Phase III PADMA study in this video featuring Sibylle Loibl, MD, PhD from the 2024 San Antonio Breast Cancer Symposium. https://t.co/oQfDvLNRJR #BreastCancer #bcsm https://t.co/brd20DTvIb
-
-
Mashup Score: 10
Natalie Wuliji, DO, and Mohamed Sorror, MD, MSc, of Fred Hutch Cancer Center and the University of Washington School of Medicine, presented results of a prospective, multicenter observational study across 13 predominantly academic centers enrolling adult patients with acute myeloid leukemia. The research aimed to evaluate the potential impact of socioeconomic disparities on receipt of hematopoietic cell transplantation in patients as well as survival outcomes (Abstract 6). Disclaimer: This video transcript
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet-
Learn about the impact of socioeconomic disparities on receipt of hematopoietic cell transplantation in this video from @ASH_hematology 2024 featuring Natalie Wuliji, DO, and Mohamed Sorror, MD, MSc https://t.co/6NjPDaOqLI #ASH2024 #leusm #Leukemia https://t.co/cEn8RdWmdh
-
-
Mashup Score: 5
Consuming a high-fiber diet after undergoing stem cell transplantation may help to reduce the risk of graft-vs-host disease by cultivating a healthy gut microbiome, according to research presented by …
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet-
Fiber-Rich Diet May Help Prevent Complications After Stem Cell Transplant according to study presented at @ASH_hematology 2024. https://t.co/ys0hnGOzoA #stemcell #GVHD #ASH24
-
Aditya Bardia, MD, of @dgsomucla discusses the efficacy and safety of trastuzumab deruxtecan vs physician’s choice of chemotherapy in this video from SABCS 2024. https://t.co/tvNuHk0JbI #SABCS24 #breastcancer https://t.co/kGxmtOY2pY